7 Insights into Methotrexate Administration, Drug Resistance & Toxicity

Thomas R. Collins is a freelance writer living in South Florida.

References

Dalrymple JM, Stamp LK, O’Donnell JL, et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2008 Nov;58(11):3299–3308.
Braun J, Kästner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008 Jan;58(1):73–81.
Khanna D, Park GS, Paulus HE, et al. Reduction of the efficacy of methotrexate by the use of folic acid: Post hoc analysis from two randomized controlled studies. Arthritis Rheum. 2005 Oct;52(10):3030–3038.

Methotrexate and its mechanism of action

Physicians at the California Rheumatology Alliance 10th Annual Medical & Scientific Meeting in San Francisco report on studies about JAK inhibitors as targeted immunomodulators and disease-modifying therapies in RA

Review of clinical research on methotrexate therapy, effect on patients’ functionality, tolerability, adverse events

Methotrexate (MTX) remains the predominant medication used by rheumatologists to treat rheumatoid arthritis (RA). Doses of 7.5–25 mg per week with daily folic acid are generally prescribed. Despite its common use, MTX must be prescribed cautiously given the potential adverse effects when taken incorrectly or without folic acid supplementation. Cases of MTX-induced cutaneous ulceration have…

References

Old Drugs Can Learn New Tricks

Janus Kinase Inhibitors Represent New Tool to Slow Rheumatoid Arthritis

2014 ACR/ARHP Annual Meeting: Methotrexate Use in Patients with RA

Case Report: RA Patient Suffers Methotrexate-Induced Cutaneous Lesions

References

Related Articles